CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP) reported FY 2025 total revenue of $3.5M, primarily from collaboration activities, amid heavy R&D investment. Operating expenses reached $668.1M, driven by $284.8M in research and development, $96.3M in acquired in-process R&D, $73.5M in general and administrative, and $213.5M net collaboration expense, resulting in a $664.6M operating loss. Other income of $86.6M partially offset costs, leading to a net loss of $581.6M or -$6 per share (basic and diluted), based on 89.9M weighted-average shares. Balance sheet remains robust with $2.27B total assets, including $347.6M cash equivalents and $1.63B marketable securities; total current assets $1.99B against $149.1M current liabilities, yielding $1.92B shareholders' equity. Cash flow showed -$345.0M used in operations, -$31.8M in investing, offset by $426.0M from financing (primarily $398.1M common shares issuance), increasing cash by $49.3M to $224.1M (including restricted). No prior year figures disclosed; strong liquidity supports ongoing gene-editing pipeline advancement despite losses typical for clinical-stage biotech.

Key Takeaways